Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

11 Background: Preclinical studies have shown combined anti-tumor effect through interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor signaling pathways. A Phase II trial (NCT01972217) in pts with mCRPC unselected by homologous recombination repair (HRR) status who previously received docetaxel demonstrated improved radiographic progression-free survival (rPFS)...

  • 123456 Profile photo of Madelyn

    PROPEL abstract — abi/pred + olaparib. Different outcomes between this trial and the MAGNITUDE trial on men withOUT HRR mutatated cancers. therefore, probably will combine parp inhibitor w/abiraterone/pred in men who are otherwise candidates for PARP inhibitors but not yet in men who are not otherwise candidates for PARP inhibitor therapy.